Cara Therapeutics to Host Industry Symposium at the Orthopaedic Trauma Association 2016 Annual Meeting
September 29 2016 - 8:00AM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
peripheral kappa opioid receptors, today announced that it will
host an industry symposium titled “Moving Beyond Mu with Kappa
Opioid Receptor Agonists - Leaving the Baggage Behind” at the
Orthopaedic Trauma Association 2016 Annual Meeting, which will be
held October 5-8, 2016 at the Gaylord National Resort &
Convention Center in National Harbor, Maryland.
The symposium will feature a discussion with
pain experts on the impact of the opioid epidemic on orthopaedic
surgery and the latest developments in analgesia, including
efficacy, safety, and abuse potential results from Cara’s acute and
chronic pain and human abuse liability studies of CR845, the
Company’s first-in-class peripherally selective kappa opioid
agonist. The findings to be presented support the view that CR845
is unlikely to be recreationally abused or lead to physical
dependence.
The symposium details are as follows:
Date: Thursday, October
6, 2016Time: 11:45 a.m. – 12:45 p.m.
ETLocation: National Harbor 6, Level 3,
Gaylord National Resort & Convention Center, National Harbor,
MDModerator: Joseph Stauffer, D.O., M.B.A.,
Chief Medical Officer, Cara Therapeutics; Assistant Professor,
Department of Anesthesiology & Critical Care Medicine, Johns
Hopkins University School of
MedicineFaculty: Hassan R. Mir, M.D.,
M.B.A., F.A.C.S., Director of Orthopaedic Residency Program,
Associate Professor, University of South Florida; Director of
Orthopaedic Trauma Research, Florida Orthopaedic Institute
For more information on the Orthopaedic Trauma
Association 2016 Annual Meeting, visit:
http://ota.org/education/2016-ota-annual-meeting/.
About CR845
CR845 is a peripherally acting kappa opioid
receptor agonist currently in development for the treatment of
acute and chronic pain and pruritus. In multiple randomized,
double-blind, placebo-controlled Phase 2 trials in patients
undergoing laparoscopic hysterectomy or bunionectomy procedures,
I.V. CR845 treatment resulted in statistically significant
reductions in both pain intensity and opioid-related side effects.
In a human abuse liability trial, I.V. CR845 demonstrated
statistically significant reductions in “drug liking,” “feeling
high,” “overall liking,” and “take drug again” scores in comparison
to I.V. pentazocine, a Schedule IV analgesic.
An oral formulation of CR845 is currently being
evaluated in a Phase 2b study in osteoarthritis patients and was
shown in a Phase 2a study to be well tolerated with twice a day
dosing for two weeks, with evidence of decreasing pain scores
during that time period.
In approximately 1,150 subjects dosed to date,
CR845 was found to be well tolerated, without incurring the
dysphoric and psychotomimetic side effects that have been reported
with centrally acting (CNS-active) kappa opioid receptor
agonists.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biotechnology company focused on developing and commercializing new
chemical entities designed to alleviate pain and pruritus by
selectively targeting peripheral kappa opioid receptors. Cara is
developing a novel and proprietary class of product candidates that
target the body's peripheral nervous system and have demonstrated
initial efficacy in patients with moderate-to-severe pain without
inducing many of the undesirable side effects typically associated
with currently available pain therapeutics.
INVESTOR CONTACT:
Jesse Baumgartner
Stern Investor Relations, Inc.
212-362-1200
Jesse@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024